疫苗生产商Moderna表示，美国食品和药物管理局(FDA)已同意审查其 流感疫苗申请，推翻了早些时候 拒绝该申请的决定。Moderna表示，FDA已经接受了其提出的修订方案，即寻求全面批准50至64岁的成 年人注射该疫苗，并加速批准65岁及以上的成年人注射该疫苗。该公司还补充称，将对老年人进行上市 后研究。 ...

格隆汇2月18日｜莫德纳(MRNA.US)涨6.6%，美国食品药品监督管理局（FDA）启动对该公司流感疫苗 的审查。 ...

每经AI快讯，2月18日，莫德纳股价上涨6.6%。 （文章来源：每日经济新闻） ...

The Food and Drug Administration has reversed its decision not to review a new flu vaccine from Moderna, the pharmaceutical company said Wednesday.Last week, the FDA sent a missive to Moderna refusing to review its new shot, saying its application did not contain adequate research – leaving the company’s president Dr. Stephen Hoge in “complete shock.”Moderna’s flu vaccine will not be reviewed by the FDA. Rawf8 – stock.adobe.comIn an exclusive interview with The Post, Hoge said he was “completely surprised a ...

The U.S. Food and Drug Administration will review the investigational seasonal flu vaccine candidate after rejecting it earlier this month. ...

Group 1 - The company's mRNA flu shot, if approved, could be available for the 2026-27 flu season [1]

A two-in-one mRNA vaccine developed by Moderna that targets seasonal influenza and COVID-19 produced robust and durable immune responses without safety concerns in a small mid-stage trial, the company... ...

Core Viewpoint - The U.S. Food and Drug Administration has accepted Moderna's application to review its influenza vaccine candidate [1] Company Summary - Moderna is advancing its influenza vaccine candidate through the regulatory process with the FDA's acceptance of its application [1]

Group 1 - The analyst has not reviewed Light & Wonder (LNWO) in nearly nine months, indicating a potential gap in recent performance analysis [1] - The analyst specializes in the U.S. restaurant industry, covering various segments including quick-service, fast casual, fine dining, and niche concepts [2] - The research firm focuses on uncovering hidden value in public equities, particularly in micro and small-cap stocks that are often overlooked [2] Group 2 - The analyst employs advanced financial modeling and sector-specific KPIs to conduct thematic research and valuation efforts [2] - The analyst's background includes an MBA in Controllership and Accounting Forensics, along with a Bachelor's in Business Administration [2] - The research has been featured on multiple platforms, indicating a broad reach and recognition in the industry [2]

Company Overview - Moderna, Inc. is a leading player in the biotech industry, recognized for its innovative mRNA technology and focus on developing vaccines and therapeutics, positioning it as a leader in the biomedical and genetics sector [1] Stock Performance - On February 16, 2026, UBS maintained a Neutral rating for Moderna, advising investors to hold the stock, with the stock priced at $42.23 and a revised price target adjusted from $34 to $36, indicating a cautious yet optimistic outlook [2] - Moderna's shares experienced a 5.3% increase on February 13, driven by investor interest in large-cap biotech companies, highlighting the positive sentiment surrounding the stock [3][6] - The stock has fluctuated between $41.23 and $44.80 on the day, with a 52-week high of $55.20 and a low of $22.28, reflecting its volatility in the market [5] Market Capitalization and Trading Volume - Moderna's market capitalization is approximately $16.5 billion, with a trading volume of 16,336,584 shares, indicating significant investor activity [4][6] Industry Sentiment - The biotech sector's improved outlook and institutional buying have contributed to positive sentiment surrounding Moderna, as investors are attracted to the company's blend of innovation and stability, recognizing its potential for sustained momentum beyond the pandemic-driven surge [4]